High stability and cooperative unfolding of α-Synuclein Oligomers

Biochemistry

Volumn 53, Issue 39, 2014, Pages 6252-6263

  Paslawski, Wojciech ^a   Andreasen, Maria ^a   Nielsen, Søren Bang ^a,b   Lorenzen, Nikolai ^a,c   Thomsen, Karen ^a   Kaspersen, Jørn Døvling ^a   Pedersen, Jan Skov ^a   Otzen, Daniel E ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b Arla Foods   (Denmark)

^c NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AGGREGATES; NEURODEGENERATIVE DISEASES;

CHEMICAL DENATURANTS; CYTOTOXIC SPECIES; DENATURANT CONCENTRATION; DISORDERED STRUCTURES; FIBRIL FORMATION; MOLECULAR PROPERTIES; PARKINSON'S DISEASE; THERAPEUTIC STRATEGY;

OLIGOMERS;

4 (DICYANOVINYL)JULOLIDINE; ALPHA SYNUCLEIN; ALPHA SYNUCLEIN OLIGOMER; MONOMER; OLIGOMER; UNCLASSIFIED DRUG; UREA; VINYL DERIVATIVE; AMYLOID;

ANIMAL EXPERIMENT; ARTICLE; CIRCULAR DICHROISM; COMPARATIVE STUDY; CONTROLLED STUDY; DYNAMIC LIGHT SCATTERING; EQUILIBRIUM CONSTANT; GEL PERMEATION CHROMATOGRAPHY; INFRARED SPECTROSCOPY; LIGHT SCATTERING; NONHUMAN; PARKINSON DISEASE; PH; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN AGGREGATION; PROTEIN PURIFICATION; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; PROTEIN UNFOLDING; RAT; TEMPERATURE; TRANSMISSION ELECTRON MICROSCOPY; X RAY CRYSTALLOGRAPHY; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; HUMAN; METABOLISM; MUTATION; PROTEIN MULTIMERIZATION; SMALL ANGLE SCATTERING; X RAY DIFFRACTION;

ALPHA-SYNUCLEIN; AMYLOID; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; HYDROGEN-ION CONCENTRATION; MICROSCOPY, ELECTRON, TRANSMISSION; MODELS, MOLECULAR; MUTATION; PARKINSON DISEASE; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; PROTEIN UNFOLDING; SCATTERING, SMALL ANGLE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TEMPERATURE; X-RAY DIFFRACTION;

EID: 84907854533     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi5007833     Document Type: Article

References (87)

1. Chiti, F. and Dobson, C. M. (2006) Protein misfolding, functional amyloid, and human disease Annu. Rev. Biochem. 75, 333-366
2. Giehm, L., Svergun, D. I., Otzen, D. E., and Vestergaard, B. (2011) Low-resolution structure of a vesicle disrupting α-synuclein oligomer that accumulates during fibrillation Proc. Natl. Acad. Sci. U.S.A. 108, 3246-3251
3. Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T., and Lansbury, P. T., Jr. (2002) Neurodegenerative disease: Amyloid pores from pathogenic mutations Nature 418, 291
4. Conway, K. A., Lee, S. J., Rochet, J. C., Ding, T. T., Williamson, R. E., and Lansbury, P. T., Jr. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy Proc. Natl. Acad. Sci. U.S.A. 97, 571-576
5. Winner, B., Jappelli, R., Maji, S. K., Desplats, P. A., Boyer, L., Aigner, S., Hetzer, C., Loher, T., Vilar, M., Campioni, S., Tzitzilonis, C., Soragni, A., Jessberger, S., Mira, H., Consiglio, A., Pham, E., Masliah, E., Gage, F. H., and Riek, R. (2011) In vivo demonstration that alpha-synuclein oligomers are toxic Proc. Natl. Acad. Sci. U.S.A. 108, 4194-4199
6. Walsh, D. M. and Selkoe, D. J. (2007) A beta oligomers-a decade of discovery J. Neurochem. 101, 1172-1184
7. Lesne, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., and Ashe, K. H. (2006) A specific amyloid-beta protein assembly in the brain impairs memory Nature 440, 352-357
8. Nilsberth, C., Westlind-Danielsson, A., Eckman, C. B., Condron, M. M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D. B., Younkin, S. G., Naslund, J., and Lannfelt, L. (2001) The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation Nat. Neurosci. 4, 887-893
9. Bernstein, S. L., Dupuis, N. F., Lazo, N. D., Wyttenbach, T., Condron, M. M., Bitan, G., Teplow, D. B., Shea, J. E., Ruotolo, B. T., Robinson, C. V., and Bowers, M. T. (2009) Amyloid-beta protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease Nat. Chem. 1, 326-331
10. Ward, S. M., Himmelstein, D. S., Lancia, J. K., and Binder, L. I. (2012) Tau oligomers and tau toxicity in neurodegenerative disease Biochem. Soc. Trans. 40, 667-671
11. Volles, M. J., Lee, S. J., Rochet, J. C., Shtilerman, M. D., Ding, T. T., Kessler, J. C., and Lansbury, P. T., Jr. (2001) Vesicle permeabilization by protofibrillar alpha-synuclein: Implications for the pathogenesis and treatment of Parkinson's disease Biochemistry 40, 7812-7819
12. Hill, S. E., Robinson, J., Matthews, G., and Muschol, M. (2009) Amyloid protofibrils of lysozyme nucleate and grow via oligomer fusion Biophys. J. 96, 3781-3790
13. Vestergaard, B., Groenning, M., Roessle, M., Kastrup, J. S., van de Weert, M., Flink, J. M., Frokjaer, S., Gajhede, M., and Svergun, D. I. (2007) A helical structural nucleus is the primary elongating unit of insulin amyloid fibrils PLoS Biol. 5 e134
14. Lorenzen, N., Cohen, S. I. A., Nielsen, S. B., Herling, T. W., Christiansen, G., Dobson, C. M., Knowles, T. P. J., and Otzen, D. (2012) Role of Elongation and Secondary Pathways in S6 Amyloid Fibril Growth Biophys. J. 102, 2167-2175
15. Kardos, J., Yamamoto, K., Hasegawa, K., Naiki, H., and Goto, Y. (2004) Direct measurement of the thermodynamic parameters of amyloid formation by isothermal titration calorimetry J. Biol. Chem. 279, 55308-55314
16. Kim, H. J., Chatani, E., Goto, Y., and Paik, S. R. (2007) Seed-dependent accelerated fibrillation of alpha-synuclein induced by periodic ultrasonication treatment J. Microbiol. Biotechnol. 17, 2027-2032
17. Morris, A. M., Watzky, M. A., and Finke, R. G. (2009) Protein aggregation kinetics, mechanism, and curve-fitting: A review of the literature Biochim. Biophys. Acta 1794, 375-397
18. Knowles, T. P., Fitzpatrick, A. W., Meehan, S., Mott, H. R., Vendruscolo, M., Dobson, C. M., and Welland, M. E. (2007) Role of intermolecular forces in defining material properties of protein nanofibrils Science 318, 1900-1903
19. Collins, S. R., Douglass, A., Vale, R. D., and Weissman, J. S. (2004) Mechanism of prion propagation: Amyloid growth occurs by monomer addition PLoS Biol. 2 e321
20. Jain, S. and Udgaonkar, J. B. (2011) Defining the pathway of worm-like amyloid fibril formation by the mouse prion protein by delineation of the productive and unproductive oligomerization reactions Biochemistry 50, 1153-1161
21. Necula, M., Kayed, R., Milton, S., and Glabe, C. G. (2007) Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct J. Biol. Chem. 282, 10311-10324
22. Souillac, P. O., Uversky, V. N., Millett, I. S., Khurana, R., Doniach, S., and Fink, A. L. (2002) Elucidation of the molecular mechanism during the early events in immunoglobulin light chain amyloid fibrillation. Evidence for an off-pathway oligomer at acidic pH J. Biol. Chem. 277, 12666-12679
23. Gellermann, G. P., Byrnes, H., Striebinger, A., Ullrich, K., Mueller, R., Hillen, H., and Barghorn, S. (2008) Abeta-globulomers are formed independently of the fibril pathway Neurobiol. Dis. 30, 212-220
24. Hong, D. P., Han, S., Fink, A. L., and Uversky, V. N. (2011) Characterization of the non-fibrillar alpha-synuclein oligomers Protein Pept. Lett. 18, 230-240
25. Lorenzen, N., Nielsen, S. B., Buell, A. K., Kaspersen, J. D., Arosio, P., Vad, B. S., Paslawski, W., Christiansen, G., Valnickova-Hansen, Z., Andreasen, M., Enghild, J. J., Pedersen, J. S., Dobson, C. M., Knowles, T. J., and Otzen, D. E. (2014) The role of stable α-synuclein oligomers in the molecular events underlying amyloid formation J. Am. Chem. Soc. 136, 3859-3868
26. Stefanis, L. (2012) alpha-Synuclein in Parkinson's disease Cold Spring Harbor Perspect. Med. 2 a009399
27. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J. T., Schols, L., and Riess, O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease Nat. Genet. 18, 106-108
28. Zarranz, J. J., Alegre, J., Gomez-Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atares, B., Llorens, V., Gomez Tortosa, E., del Ser, T., Munoz, D. G., and de Yebenes, J. G. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia Ann. Neurol. 55, 164-173
29. Hamilton, B. A. (2004) alpha-Synuclein A53T substitution associated with Parkinson disease also marks the divergence of Old World and New World primates Genomics 83, 739-742
30. Chartier-Harlin, M. C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., Waucquier, N., Defebvre, L., Amouyel, P., Farrer, M., and Destee, A. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease Lancet 364, 1167-1169
31. Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., Lincoln, S., Crawley, A., Hanson, M., Maraganore, D., Adler, C., Cookson, M. R., Muenter, M., Baptista, M., Miller, D., Blancato, J., Hardy, J., and Gwinn-Hardy, K. (2003) alpha-Synuclein locus triplication causes Parkinson's disease Science 302, 841
32. Appel-Cresswell, S., Vilarino-Guell, C., Encarnacion, M., Sherman, H., Yu, I., Shah, B., Weir, D., Thompson, C., Szu-Tu, C., Trinh, J., Aasly, J. O., Rajput, A., Rajput, A. H., Stoessl, A. J., and Farrer, M. J. (2013) Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease Mov. Disord. 28, 811-813
33. Lesage, S., Anheim, M., Letournel, F., Bousset, L., Honore, A., Rozas, N., Pieri, L., Madiona, K., Durr, A., Melki, R., Verny, C., and Brice, A. (2013) G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome Ann. Neurol. 73, 459-471
34. Chandra, S., Gallardo, G., Fernandez-Chacon, R., Schluter, O. M., and Sudhof, T. C. (2005) Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration Cell 123, 383-396
35. Takenouchi, T., Hashimoto, M., Hsu, L. J., Mackowski, B., Rockenstein, E., Mallory, M., and Masliah, E. (2001) Reduced neuritic outgrowth and cell adhesion in neuronal cells transfected with human alpha-synuclein Mol. Cell. Neurosci. 17, 141-150
36. Tsuboi, K., Grzesiak, J. J., Bouvet, M., Hashimoto, M., Masliah, E., and Shults, C. W. (2005) Alpha-synuclein overexpression in oligodendrocytic cells results in impaired adhesion to fibronectin and cell death Mol. Cell. Neurosci. 29, 259-268
37. Bartels, T., Choi, J. G., and Selkoe, D. J. (2011) alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation Nature 477, 107-110
38. Fauvet, B., Mbefo, M. K., Fares, M. B., Desobry, C., Michael, S., Ardah, M. T., Tsika, E., Coune, P., Prudent, M., Lion, N., Eliezer, D., Moore, D. J., Schneider, B., Aebischer, P., El-Agnaf, O. M., Masliah, E., and Lashuel, H. A. (2012) alpha-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer J. Biol. Chem. 287, 15345-15364
39. Wang, W., Perovic, I., Chittuluru, J., Kaganovich, A., Nguyen, L. T., Liao, J., Auclair, J. R., Johnson, D., Landeru, A., Simorellis, A. K., Ju, S., Cookson, M. R., Asturias, F. J., Agar, J. N., Webb, B. N., Kang, C., Ringe, D., Petsko, G. A., Pochapsky, T. C., and Hoang, Q. Q. (2011) A soluble alpha-synuclein construct forms a dynamic tetramer Proc. Natl. Acad. Sci. U.S.A. 108, 17797-17802
40. Dettmer, U., Newman, A. J., Luth, E. S., Bartels, T., and Selkoe, D. (2013) In vivo cross-linking reveals principally oligomeric forms of alpha-synuclein and beta-synuclein in neurons and non-neural cells J. Biol. Chem. 288, 6371-6385
41. Binolfi, A., Theillet, F. X., and Selenko, P. (2012) Bacterial in-cell NMR of human alpha-synuclein: a disordered monomer by nature? Biochem. Soc. Trans. 40, 950-954
42. Coelho-Cerqueira, E., Carmo-Goncalves, P., Sa Pinheiro, A., Cortines, J., and Follmer, C. (2013) alpha-Synuclein as an intrinsically disordered monomer-fact or artefact? FEBS J. 280, 4915-4927
43. Weinreb, P. H., Zhen, W., Poon, A. W., Conway, K. A., and Lansbury, P. T., Jr. (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded Biochemistry 35, 13709-13715
44. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., and Goedert, M. (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies Proc. Natl. Acad. Sci. U.S.A. 95, 6469-6473
45. Fink, A. L. (1998) Protein aggregation: Folding aggregates, inclusion bodies and amyloid Folding Des. 3, R9-23
46. Celej, M. S., Sarroukh, R., Goormaghtigh, E., Fidelio, G. D., Ruysschaert, J. M., and Raussens, V. (2012) Toxic prefibrillar alpha-synuclein amyloid oligomers adopt a distinctive antiparallel beta-sheet structure Biochem. J. 443, 719-726
47. Cremades, N., Cohen, S. I., Deas, E., Abramov, A. Y., Chen, A. Y., Orte, A., Sandal, M., Clarke, R. W., Dunne, P., Aprile, F. A., Bertoncini, C. W., Wood, N. W., Knowles, T. P., Dobson, C. M., and Klenerman, D. (2012) Direct observation of the interconversion of normal and toxic forms of alpha-synuclein Cell 149, 1048-1059
48. Outeiro, T. F., Putcha, P., Tetzlaff, J. E., Spoelgen, R., Koker, M., Carvalho, F., Hyman, B. T., and McLean, P. J. (2008) Formation of toxic oligomeric alpha-synuclein species in living cells PloS One 3 e1867
49. Stockl, M. T., Zijlstra, N., and Subramaniam, V. (2013) Alpha-synuclein oligomers: an amyloid pore? Insights into mechanisms of alpha-synuclein oligomer-lipid interactions Mol. Neurobiol. 47, 613-621
50. Lashuel, H. A., Overk, C. R., Oueslati, A., and Masliah, E. (2013) The many faces of alpha-synuclein: from structure and toxicity to therapeutic target Nat. Rev. Neurosci. 14, 38-48
51. Kalia, L. V., Kalia, S. K., McLean, P. J., Lozano, A. M., and Lang, A. E. (2013) alpha-Synuclein oligomers and clinical implications for Parkinson disease Ann. Neurol. 73, 155-169
52. Tsigelny, I. F., Sharikov, Y., Wrasidlo, W., Gonzalez, T., Desplats, P. A., Crews, L., Spencer, B., and Masliah, E. (2012) Role of alpha-synuclein penetration into the membrane in the mechanisms of oligomer pore formation FEBS J. 279, 1000-1013
53. van Rooijen, B. D., Claessens, M. M., and Subramaniam, V. (2010) Membrane Permeabilization by Oligomeric alpha-Synuclein: In Search of the Mechanism PloS One 5 e14292
54. van Rooijen, B. D., Claessens, M. M., and Subramaniam, V. (2009) Lipid bilayer disruption by oligomeric alpha-synuclein depends on bilayer charge and accessibility of the hydrophobic core Biochim. Biophys. Acta 1788, 1271-1278
55. Polymeropoulos, M. H., Higgins, J. J., Golbe, L. I., Johnson, W. G., Ide, S. E., Di Iorio, G., Sanges, G., Stenroos, E. S., Pho, L. T., Schaffer, A. A., Lazzarini, A. M., Nussbaum, R. L., and Duvoisin, R. C. (1996) Mapping of a gene for Parkinson's disease to chromosome 4q21-q23 Science 274, 1197-1199
56. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997) Alpha-synuclein in Lewy bodies Nature 388, 839-840
57. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Di Iorio, G., Golbe, L. I., and Nussbaum, R. L. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease Science 276, 2045-2047
58. Uversky, V. N. (2010) Mysterious oligomerization of the amyloidogenic proteins FEBS J. 277, 2940-2953
59. Fandrich, M. (2012) Oligomeric intermediates in amyloid formation: structure determination and mechanisms of toxicity J. Mol. Biol. 421, 427-440
60. Paslawski, W., Mysling, S., Thomsen, K., Jørgensen, T. J. D., and Otzen, D. E. (2014) Co-existence of two different α-synuclein oligomers with different core structures determined by Hydrogen/Deuterium Exchange Mass Spectrometry Angew. Chem., Int. Ed. Engl. 53, 7560-7563 10.1002/anie.201400491
61. Lorenzen, N., Nielsen, S. B., Yoshimura, Y., Andersen, C. B., Betzer, C., Vad, B. S., Kaspersen, J. D., Christiansen, G., Pedersen, J. S., Jensen, P. H., Mulder, F. A., and Otzen, D. E. (2014) How epigallocatechin gallate can inhibit α-synuclein oligomer toxicity in vitro J. Biol. Chem. 289, 21299-21310 10.1074/jbc.M114.554667
62. Lorenzen, N., Lemminger, L., Pedersen, J. N., Nielsen, S. B., and Otzen, D. E. (2013) The N-terminus of α-synuclein is essential for both monomeric and oligomeric interactions with membranes FEBS Lett. 588, 497-502
63. Lindgren, M., Sorgjerd, K., and Hammarstrom, P. (2005) Detection and characterization of aggregates, prefibrillar amyloidogenic oligomers, and protofibrils using fluorescence spectroscopy Biophys. J. 88, 4200-4212
64. Huang, C., Ren, G., Zhou, H., and Wang, C. C. (2005) A new method for purification of recombinant human alpha-synuclein in Escherichia coli Protein Expression Purif. 42, 173-177
65. Giehm, L., Lorenzen, N., and Otzen, D. E. (2011) Assays for alpha-synuclein aggregation Methods 53, 295-305
66. Giehm, L. and Otzen, D. E. (2010) Strategies to increase the reproducibility of protein fibrillization in plate reader assays Anal. Biochem. 400, 270-281
67. Nesgaard, L., Vad, B., Christiansen, G., and Otzen, D. (2009) Kinetic partitioning between aggregation and vesicle permeabilization by modified ADan Biochim. Biophys. Acta 1794, 84-93
68. Abramoff, M. D., Magelhaes, P. J., and Ram, S. J. (2004) Image Processing with ImageJ Biophotonics Int. 11, 36-42
69. Royer, C. A., Mann, C. J., and Matthews, C. R. (1993) Resolution of the fluorescence equilibrium unfolding profile of trp aporepressor using single tryptophan mutants Protein Sci. 2, 1844-1852
70. Pace, C. N. (1986) Determination and analysis of urea and guanidine hydrochloride denaturation curves Methods Enzymol. 131, 266-279
71. Mogensen, J. E., Ibsen, H., Lund, J., and Otzen, D. E. (2004) Elimination of an off-pathway folding intermediate by a single point mutation Biochemistry 43, 3357-3367
72. Pedersen, J. S. (2004) A flux- and background-optimized version of the NanoSTAR small-angle X-ray scattering camera for solution scattering J. Appl. Crystallogr. 37, 368-380
73. Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., and Glabe, C. G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis Science 300, 486-489
74. Celej, M. S., Jares-Erijman, E. A., and Jovin, T. M. (2008) Fluorescent N-arylaminonaphthalene sulfonate probes for amyloid aggregation of alpha-synuclein Biophys. J. 94, 4867-4879
75. Bolognesi, B., Kumita, J. R., Barros, T. P., Esbjorner, E. K., Luheshi, L. M., Crowther, D. C., Wilson, M. R., Dobson, C. M., Favrin, G., and Yerbury, J. J. (2010) ANS binding reveals common features of cytotoxic amyloid species ACS Chem. Biol. 5, 735-740
76. Lindgren, M., Sörgjerd, K., and Hammarström, P. (2005) Detection and Characterization of Aggregates, Prefibrillar Amyloidogenic Oligomers, and Protofibrils Using Fluorescence Spectroscopy Biophys. J. 88, 4200-4212
77. Ban, T., Hamada, D., Hasegawa, K., Naiki, H., and Goto, Y. (2003) Direct observation of amyloid fibril growth monitored by thioflavin T fluorescence J. Biol. Chem. 278, 16462-16465
78. Dusa, A., Kaylor, J., Edridge, S., Bodner, N., Hong, D. P., and Fink, A. L. (2006) Characterization of oligomers during α-synuclein aggregation using intrinsic tryptophan fluorescence Biochemistry 45, 2752-2760
79. Munishkina, L. A., Phelan, C., Uversky, V. N., and Fink, A. L. (2003) Conformational behavior and aggregation of α-synuclein in organic solvents: Modeling the effects of membranes Biochemistry 42, 2720-2730
80. Luk, K. C., Hyde, E. G., Trojanowski, J. Q., and Lee, V. M. (2007) Sensitive fluorescence polarization technique for rapid screening of α-synuclein oligomerization/fibrillization inhibitors Biochemistry 46, 12522-12529
81. Fink, A. L. (2006) The aggregation and fibrillation of α-synuclein Acc. Chem. Res. 39, 628-634
82. Singh, P. K., Kotia, V., Ghosh, D., Mohite, G. M., Kumar, A., and Maji, S. K. (2013) Curcumin modulates α-synuclein aggregation and toxicity ACS Chem. Neurosci. 4, 393-407
83. Putcha, P., Danzer, K. M., Kranich, L. R., Scott, A., Silinski, M., Mabbett, S., Hicks, C. D., Veal, J. M., Steed, P. M., Hyman, B. T., and McLean, P. J. (2010) Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity J. Pharmacol. Exp. Ther. 332, 849-857
84. McLean, P. J., Klucken, J., Shin, Y., and Hyman, B. T. (2004) Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro Biochem. Biophys. Res. Commun. 321, 665-669
85. Riedel, M., Goldbaum, O., Schwarz, L., Schmitt, S., and Richter-Landsberg, C. (2010) 17-AAG induces cytoplasmic alpha-synuclein aggregate clearance by induction of autophagy PloS One 5 e8753
86. Ehrnhoefer, D. E., Bieschke, J., Boeddrich, A., Herbst, M., Masino, L., Lurz, R., Engemann, S., Pastore, A., and Wanker, E. E. (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers Nat. Struct. Mol. Biol. 15, 558-566
87. Grelle, G., Otto, A., Lorenz, M., Frank, R. F., Wanker, E. E., and Bieschke, J. (2011) Black tea theaflavins inhibit formation of toxic amyloid-β and α-synuclein fibrils Biochemistry 50, 10624-10636